Literature DB >> 7694946

Sneddon's syndrome--an inflammatory disorder of small arteries followed by smooth muscle proliferation. Immunohistochemical and ultrastructural evidence.

N Sepp1, B Zelger, G Schuler, N Romani, P Fritsch.   

Abstract

Sneddon's syndrome is a rare, but potentially severe, arterioocclusive disorder characterized by generalized livedo racemosa of the skin and various central nervous symptoms due to occlusion of medium-sized arteries of unknown cause. We have recently shown that, in skin, small to medium-sized arteries of the dermis-subcutis boundary are affected in a stage-specific sequence. An initial phase (stage I), characterized by the attachment of lymphohistiocytic cells and detachment of endothelial cells (endothelitis), is followed by an early phase (stage II), which displays partial or complete occlusion of the lumen by a plug of lymphohistiocytic cells and fibrin. In an intermediate phase (stage III), the occluding plug is replaced by proliferating subendothelial cells accompanied by the occurrence of dilated capillaries in the adventitia of the occluded vessel. The late phase (stage IV) shows fibrosis and shrinkage of the affected vessels. We investigated sections of paraffin-embedded specimens of 18 patients by immunohistochemistry using a panel of antibodies to detect endothelial cells, macrophages, T cells, smooth muscle-specific actin, and intermediate filaments (vimentin, desmin). We found that the cells involved in subendothelial proliferation were vimentin and actin positive (smooth-muscle-specific), but desmin negative and thus displayed the phenotype characteristic of smooth muscle cells, which was confirmed by ultrastructural studies. CD3+, UCHL-1+, and HLA-DR+ cells constituted a significant proportion of the inflammatory infiltrate in the early stages. The endothelial cells in the dilated capillaries of the adventitia were strongly HLA-DR positive. In later stages, endothelial cells and leukocytes were scarce. The data confirm the hypothesis that Sneddon's syndrome starts as an inflammatory and possibly immunologically mediated disorder, leading to a migration and proliferation of smooth cells of small arteries, resulting in a partial or complete narrowing of the vessel lumen.

Entities:  

Mesh:

Year:  1995        PMID: 7694946     DOI: 10.1097/00000478-199504000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Improvement of neurological symptoms and memory and emotional status in a case of seronegative Sneddon syndrome with cyclophosphamide.

Authors:  Peter M Hannon; Sheng-Han Kuo; Adriana M Strutt; Michele K York; Joseph S Kass
Journal:  Clin Neurol Neurosurg       Date:  2010-05-04       Impact factor: 1.876

Review 2.  Familial inflammatory Sneddon's syndrome-case report and review of the literature.

Authors:  M Szmyrka-Kaczmarek; T Daikeler; D Benz; I Koetter
Journal:  Clin Rheumatol       Date:  2004-08-31       Impact factor: 2.980

3.  Digital ulcers secondary to Sneddon's syndrome successfully treated with Bosentan: not only useful in Systemic Sclerosis.

Authors:  Tommaso Barnini; Elena Silvestri; Giacomo Emmi; Mario Milco D'Elios; Lorenzo Emmi
Journal:  Auto Immun Highlights       Date:  2012-10-09

Review 4.  Sneddon's syndrome: a comprehensive review of the literature.

Authors:  Shengjun Wu; Ziqi Xu; Hui Liang
Journal:  Orphanet J Rare Dis       Date:  2014-12-31       Impact factor: 4.123

5.  Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Authors:  Dolores Pérez; Ljudmila Stojanovich; Laura Naranjo; Natasa Stanisavljevic; Gordana Bogdanovic; Manuel Serrano; Antonio Serrano
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

Review 6.  Bar Code Reader - an algorithmic approach to cutaneous occluding vasculopathies? part II medium vessel vasculopathies.

Authors:  Gudrun Ratzinger; Bettina G Zelger; Bernhard W Zelger
Journal:  J Dtsch Dermatol Ges       Date:  2019-11       Impact factor: 5.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.